EyePoint (EYPT) Cost of Revenue (2019 - 2026)
EyePoint (EYPT) posted Cost of Revenue of $528000.0 for Q1 2026, up 40.8% sequentially from $375000.0 in Q4 2025, and down 34.41% YoY from $805000.0 in Q1 2025.
Analysis
EyePoint (EYPT) Cost of Revenue (2019 - 2026) Analysis & Trends
EyePoint has reported Cost of Revenue for 8 years, with the latest figure at $528000.0 in Q1 2026.
- Quarterly Cost of Revenue fell 34.41% year-over-year to $528000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.8 million (down 52.39% YoY) and the FY2025 annual result came in at $2.1 million, down 44.34% from the prior year.
- Cost of Revenue rose to $528000.0 in Q1 2026 per EYPT's latest filing, from $375000.0 in the prior quarter.
- Over five years, Cost of Revenue peaked at $3.4 million in Q4 2022 and troughed at $165000.0 in Q2 2025.
- A 5-year average of $1.1 million and a median of $816000.0 in 2024 frame the typical range for Cost of Revenue.
- The sharpest annual moves came in 2022 and 2025: Cost of Revenue climbed 27.84% in 2022, then plunged 88.22% in 2025.
- Over 5 years, Cost of Revenue stood at $3.4 million in 2022, then tumbled by 70.73% to $998000.0 in 2023, then dropped by 18.24% to $816000.0 in 2024, then tumbled by 54.04% to $375000.0 in 2025, then surged by 40.8% to $528000.0 in 2026.
- According to Business Quant data, Cost of Revenue over the past three periods registered $528000.0, $375000.0, and $721000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cost of Rev (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 489.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 360.70 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 145.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 93.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 174.53 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 298.26 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 67.21 Mn |
| 10 | EyePoint | 398.53 Mn | 218.06 Mn | 507,000.00 | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | 528,000.00 |
| Dec 31, 2025 | 375,000.00 |
| Sep 30, 2025 | 721,000.00 |
| Jun 30, 2025 | 165,000.00 |
| Mar 31, 2025 | 805,000.00 |
| Dec 31, 2024 | 816,000.00 |
| Sep 30, 2024 | 736,000.00 |
| Jun 30, 2024 | 1.40 Mn |
| Mar 31, 2024 | 759,000.00 |
| Dec 31, 2023 | 998,000.00 |
| Sep 30, 2023 | 1.20 Mn |
| Jun 30, 2023 | 1.79 Mn |
| Mar 31, 2023 | 640,000.00 |
| Dec 31, 2022 | 3.41 Mn |
| Sep 30, 2022 | 1.41 Mn |
| Jun 30, 2022 | 1.73 Mn |
| Mar 31, 2022 | 1.78 Mn |
| Dec 31, 2021 | 3.03 Mn |
| Sep 30, 2021 | 1.83 Mn |
| Jun 30, 2021 | 1.93 Mn |